Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4)
Endometrioid Adenocarcinoma
Explore 18 assets in Endometrioid Adenocarcinoma →Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Sutro Biopharma, Inc.
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
31Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03748186CT.gov Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrioid Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4) (this asset) | Sutro Biopharma, Inc. | P1 | CC · 46 |
| Defactinib | University of Oklahoma | P2 | B |
| Patent Blue Violet | Centre Oscar Lambret | P3 | B |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| Indocyanine Green | Centre Oscar Lambret | P3 | B |
| Avutometinib | University of Oklahoma | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
| Cediranib | National Cancer Institute (NCI) | P2 | B |
| Temsirolimus | MedSIR | P2 | B |
+20 more in the Endometrioid Adenocarcinoma cohort
Other indications for Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P1/2 | CCC · 49 |
| Ovarian Carcinoma | — | P1 | CC · 43 |
| Primary Peritoneal Carcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4) in Endometrioid Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-188412-bis4-azidomethyl-l-phenylalanine-anti-human-folate-receptor-human-mus-musculus-monoclonal-sp8166-1-chain-disulfide-with-human-mus-musculus-monoclonal-sp8166-chain-dimer-click-reaction-product-with-3-4-n-4-1112-didehydrodibenzbfazocin-56h-yl-14-dioxobutyl-l-valyl-n5-aminocarbonyl-l-ornithylaminophenylmethoxycarbonylamino-n-trimethyl-l-phenylalanyl-n-1s2e-3-carboxy-1-1-methylethyl-2-buten-1-yl-n3-dimethyl-l-valinamide-14-endometrioid-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →